Opportunity Analyzer: Diabetic Foot Ulcers – Opportunity Analysis and Forecast to 2025
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData estimates sales of diabetic foot ulcer (DFU) and diabetic foot infection (DFI) drugs to be approximately $292.1M across the 7MM in 2015, encompassing the US, 5EU, and Japan. DFU sales alone accounting for $118.7M across the 7MM. The DFU, DFI market will grow at a CAGR of 11.6% over the forecast period, reaching sales of $873.4M by 2025. The US is the largest market for DFU, DFI therapies, contributing approximately 62% of total sales in the base year. GlobalData expects the uptake a novel wound healing therapy (FirstString's Granexin) to be the strongest driver of growth in the DFU market in the 7MM, reaching sales of $570.3M in 2025. Despite the anticipated launch of Granexin, there is ample opportunity for pipeline drugs targeting the subset of DFUs that are ischemic. Difficulty of successfully developing a DFU or DFI candidate is expected to be the strongest barrier. There have been multiple Phase III DFU and DFI clinical trial terminations in the past five years alone (mainly due to trials failing to meet primary endpoints), leaving the market void of any new DFU drugs for almost two decades.
Scope
Overview of DFUs and DFIs, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Annualized DFU therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the DFU and DFI therapeutics market.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global DFU and DFI therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Highlights
In addition to standard of care (SOC), Regranex and Fiblast have been the only wound healing pharmacological drugs used to treat DFUs in the US and Japan respectively. The efficacy of these agents is disputed among KOLs, with the majority of experts expressing dissatisfaction with these limited options. Therefore, there is a considerable need for additional therapies within the indication. What are the other main unmet needs in this market?
The current late-stage DFU pipeline encompasses one novel synthetic bioactive peptide, FirstString’s Granexin, which binds the ZO1 protein, and stabilizes connexin 43 gap junctions to reduce excessive inflammation and promote normal tissue regeneration. Will Granexin make a significant impact on the DFU market?
There continues to be an increase in DFU diagnosed prevalence across the 7MM over the past 10 years. How will epidemiological changes impact the growth of the future market? Overall, which of the major markets is the most lucrative within the DFU space?
Advanced Tissue Sciences
CoDa Therapeutics
FirstString Research
Genentech
GlaxoSmithKline (GSK)
Johnson & Johnson (J&J)
Healthpoint Biotherapeutics Kaken Pharmaceutical
Lakewood-Amedex
MiMedx
Relief Therapeutics
Scios
Shire
Shire Regenerative Medicine
Smith & Nephew
Stryker Biotech
Olympus
Olympus Biotech
Organogenesis
Osiris Therapeutics
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.